RBC Capital Upgrades Sagent Pharmaceuticals (SGNT) to Outperform
Tweet
Share
E-mailGet Alerts SGNT Hot Sheet
Price: $21.76 --0%
Rating Summary:
1 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 10
Rating Summary:
1 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 10
Join SI Premium – FREE
RBC Capital upgraded Sagent Pharmaceuticals (NASDAQ: SGNT) from Sector Perform to Outperform.
For an analyst ratings summary and ratings history on Sagent Pharmaceuticals click here. For more ratings news on Sagent Pharmaceuticals click here.
Shares of Sagent Pharmaceuticals closed at $25.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Bank of America (BAC) to Outperform, 'Underearning Firms Shouldn’t Trade at a Discount'
- RBC Capital Starts Inspire Medical Systems (INSP) at Outperform
- Redburn-Atlantic Upgrades Shift4 Payments (FOUR) to Neutral Citing Balanced Risk/Reward Offering
Create E-mail Alert Related Categories
UpgradesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
